What is Adaptilens?
Founded in 2019 and headquartered in Chestnut Hill, Massachusetts, Adaptilens is focused on the development of advanced intraocular lenses. Operating within the dynamic eyewear sector, the company aims to innovate and enhance vision correction technologies. The recent influx of capital suggests a pivotal moment for Adaptilens, likely enabling the expansion of its research and development efforts, scaling of manufacturing capabilities, and broader market penetration.
How much funding has Adaptilens raised?
Adaptilens has raised a total of $19.1M across 2 funding rounds:
Angel/Seed
$1.6M
Series A
$17.5M
Angel/Seed (2020): $1.6M with participation from Pillar VC and Accanto
Series A (2024): $17.5M led by Pillar VC
Key Investors in Adaptilens
Pillar VC
Pillar VC is a Boston-based venture capital firm specializing in early-stage and seed funding, aimed at supporting founders in their professional and personal growth. The firm is dedicated to backing entrepreneurs from the inception of their ideas, guiding them from concept to real-world application. Through a unique approach that emphasizes alignment between investors and founders, Pillar VC offers resources, tools, and mentorship to help startups thrive. Their intended clients include innovative founders across various sectors, including AI/ML, biotech, consumer products, enterprise solutions, and healthcare.
Accanto
Accanto is an entity that has participated in Adaptilens's funding rounds. Further details regarding its investment focus or specialization are not publicly available, but its involvement suggests a strategic interest in the intraocular lens development sector.
What's next for Adaptilens?
The substantial enterprise-level funding, particularly the recent strategic investment, positions Adaptilens for accelerated growth and market leadership. This capital infusion is expected to fuel product development, clinical trials, and commercialization strategies. Investors are betting on Adaptilens' potential to disrupt the intraocular lens market with its innovative technology, signaling a strong outlook for the company's future expansion and its contribution to vision care.
See full Adaptilens company page
